1. Market Research
  2. > Pharmaceutical
  3. > Therapy
  4. > Oncology Market Trends
RAS Targeting Therapies by Target Indication, Type of Molecule, Type of Therapy, and Route of Administration, Key Geographical Regions : Industry Trends and Global Forecasts, 2021-2031

RAS Targeting Therapies by Target Indication, Type of Molecule, Type of Therapy, and Route of Administration, Key Geographical Regions : Industry Trends and Global Forecasts, 2021-2031

  • August 2021
  • 131 pages
  • ID: 6154592
  • Format: PDF
  • Roots Analysis Private Ltd.

Summary

Table of Contents

INTRODUCTION
Close to 10 million fatalities reported in 2020 were observed to be associated with cancer, which is believed to be one of the leading causes of death, globally. , One of the primary reasons for the high mortality rate associated with this condition is anticipated to be late diagnosis, which eventually results in delayed treatment, further leading to severe compromises with chances of survival of a patient. Moreover, post the onset of the COVID-19 pandemic, the treatment of cancer patients has become arduous, as patient visits are being cancelled by healthcare facilities in order to preserve resources and prevent patients from getting infected with SARS-CoV-2. Further, as per the National Cancer Institute, the delay in screening and treatment of cancer patients due to the COVID-19 pandemic is likely to result in 10,000 deaths, which could have been otherwise prevented, over the next decade. Specifically, in 2020, the global prevalence of human cancers was estimated to be 50.5 million; of this, majority of the cases were reported to be of breast cancer and lung cancer. Since a large share of the population remains affected with various oncological indications, cancer therapeutics continue to be one of the most active segments, in terms of drug development efforts, within the pharmaceutical industry.

Given the complexities associated with conventional cancer treatment options, such as chemotherapy and radiation therapy, drug developers engaged in this domain have shifted their focus on the development of drugs against specific oncogenic mutations that are primarily responsible for the disease development and / or progression. It is worth mentioning that one such target (RAS), which was previously considered undruggable, was found to be associated with 30% of cancers in humans. Over the years, several drug candidates have been evaluated to target specific RAS mutated genes. In 2021, LUMAKRAS™ (sotorasib), a RAS targeting small molecule was approved by the USFDA for the treatment of metastatic non-small cell lung cancer in patients with KRAS G12C mutations. Given its high efficacy and good safety profile, significant efforts are being made to evaluate the potential of the aforementioned drug across multiple solid tumor indications, such as colorectal cancer. Presently, several companies (including big pharma players), independently or in collaboration with other stakeholders, are actively engaged in the development of RAS targeting therapies. Given the lucrative opportunity associated with these targets, this domain has gained attention of both private and public investors in the past few years. As more candidates are likely to progress towards advanced stages of development, we expect the market to witness aggressive growth in the foreseen future

SCOPE OF THE REPORT
The ‘RAS Targeting Therapies by Target Indication (Acute Myeloid Leukemia, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Phelan-McDermid Syndrome, and Skin Cancer), Type of Molecule (Biologic and Small Molecule), Type of Therapy (Monotherapy and Combination Therapy), and Route of Administration (Intravenous, Intramuscular, Intradermal, Intraocular, Intraperitoneal, Oral, and Subcutaneous), Key Geographical Regions (North America, Europe, Asia-Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2021-2031, report features an extensive study of the current landscape, offering an informed opinion on the likely evolution of this industry, over the next decade. Further, the study underlines an in-depth analysis of players engaged in the development of RAS targeting therapies.

Amongst other elements, the report features:
A detailed overview of the current market landscape of RAS targeting therapies, along with information on several relevant parameters, such as current status of development (marketed, clinical, pre-clinical and discovery), phase of development (phase III, phase II, phase I / II and phase I), type of molecule (biologic and small molecule), type of therapy (monotherapy and combination therapy), target therapeutic area (blood cancer, colorectal cancer, esophageal cancer, head and neck cancer, lung cancer, pancreatic cancer, skin cancer, and undisclosed solid tumors), target gene (HRAS, KRAS and NRAS), line of treatment and route of administration (intravenous, intramuscular, intradermal, intraocular, intraperitoneal, oral and subcutaneous), In addition, it presents details of companies engaged in the development of RAS targeting therapies, based on several relevant parameters, such as year of establishment, employee count, and geographical presence.
An in-depth analysis of completed, ongoing and planned clinical trials of various RAS targeting therapies, based on several relevant parameters, such as trial registration year, trial phase, trial recruitment status, enrolled patient population, study design, leading industry sponsors / collaborators (in terms of number of trials conducted), trial focus, target indication, most popular indications and regional distribution of trials.
An insightful competitive analysis, highlighting the key players engaged in the domain (on the basis of the strength of their respective development portfolios), along with information on several relevant parameters, such as company size and stage of development of lead molecules.
Elaborate profiles of the key players engaged in offering RAS targeting therapies. Each profile features a brief overview of the company, details on its product portfolio, recent developments and an informed future outlook.
A detailed review of close to 1,600 peer-reviewed, scientific articles related to research on RAS targeting therapies, which have been published between January 2020 and April 2021. It also discusses the trends across year of publication, focus area, type of molecule, popular keywords, and key journals (in terms of number of articles published in this domain and impact factor of the journal).
An analysis of the recent partnerships inked between various players engaged in the development of RAS targeting therapies, during the period 2016-2021. Additionally, it includes a brief description of the various types of partnership models (such as R&D agreements, licensing agreements (specific to affiliated technology platforms and product candidates), product development and commercialization agreements, clinical trial agreements) that have been adopted by stakeholders engaged in this domain, during the period 2016-2021.
A detailed analysis of various investments, such as venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings that were undertaken by engaged in this domain, during the period 2016-2021.
An elaborate discussion on the various commercialization strategies that have been adopted by drug developers engaged in this domain across different stages of therapy development, including prior to drug launch, at / during drug launch and post-marketing stage.

One of the key objectives of the report was to estimate the existing market size and future growth potential associated with RAS targeting therapies, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption rates and likely annual treatment cost of RAS targeting therapies, we have developed informed estimates on the evolution of the market over the coming decade. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] target indication (acute myeloid leukemia, colorectal cancer, head and neck cancer, lung cancer, ovarian cancer, pancreatic cancer, Phelan-Mcdermid syndrome and skin cancer), [B] type of molecule (biologic and small molecule), [C] type of therapy (monotherapy, combination therapy), [D] route of administration (intravenous, intramuscular, intradermal, intraocular, intraperitoneal, oral, and subcutaneous), and [E] key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World). In order to account for the future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we have conducted interviews / surveys with various experts in this domain (academia, industry and other associations) in order to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market till 2031, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information

KEY QUESTIONS ANSWERED
Which are the key candidates being developed at preclinical and clinical stages of development?
What are the key therapeutic indications for which RAS targeting therapies are being investigated?
What are the key challenges faced by stakeholders engaged in this domain?
Who are the leading industry and non-industry players engaged in the development of RAS targeting therapies?
What are the key geographies where research focused on RAS mutated cancer is being conducted?
Who are the key investors in this domain?
What kind of partnership models are commonly adopted by industry stakeholders?
What are the key value drivers that are likely to influence the evolution of this upcoming market?
How is the current and future market opportunity likely to be distributed across key market segments?

CHAPTER OUTLINES
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the RAS targeting therapies market and its likely evolution in the short to mid term and long term.

Chapter 3 provides a general introduction to various aspects of mutated RAS genes. In addition, it includes information on the role of RAS targeting therapies in the treatment of cancer, including details on the RAS gene mutations and the type of molecules that are being developed. Further, it highlights various challenges associated with the use of RAS targeting therapies and its future perspectives.

Chapter 4 provides an overview of more than 85 molecules that are currently under development for the treatment of various cancer indications, along with a detailed analysis of these molecules, based on current status of development (marketed, clinical, pre-clinical and discovery), phase of development (phase III, phase II, phase I / II and phase I), type of molecule (biologic and small molecule), type of therapy (monotherapy and combination therapy), target therapeutic area (blood cancer, colorectal cancer, esophageal cancer, head and neck cancer, lung cancer, pancreatic cancer, skin cancer, and undisclosed solid tumors), target gene (HRAS, KRAS and NRAS), line of treatment and route of administration (intravenous, intramuscular, intradermal, intraocular, intraperitoneal, oral and subcutaneous), In addition, it presents details of companies engaged in the development of RAS targeting therapies, based on several relevant parameters, such as year of establishment, employee count, and geographical presence.

Chapter 5 provides a detailed analysis of more than 120 completed, ongoing and planned clinical studies of RAS targeting therapies, based on several relevant parameters, such as trial registration year, trial phase, trial recruitment status, enrolled patient population, study design, leading industry sponsors / collaborators (in terms of number of trials conducted), trial focus, target indication, most popular indications and regional distribution of trials.

Chapter 6 features an insightful competitive analysis, highlighting the key players engaged in this domain (on the basis of the strength of their respective development portfolios), along with information on several relevant parameters, such as company size and stage of development of lead molecules.

Chapter 7 includes detailed profiles of the key players (shortlisted based on number of pipeline products) engaged in offering RAS targeting therapies. Each profile includes a brief overview of the company, details on its product portfolio, recent developments and an informed future outlook.

Chapter 8 provides a detailed review of close to 1,600 peer-reviewed, scientific articles related to research on RAS targeting therapies, which have been published between January 2020 and April 2021. It also discusses the trends across year of publication, focus area, type of molecule, popular keywords, and key journals (in terms of number of articles published in this domain and impact factor of the journal).

Chapter 9 features a detailed analysis of recent partnerships inked between various stakeholders engaged in this domain, during the period 2016-2021. Additionally, it includes a brief description of the various types of partnership models (such as R&D agreements, licensing agreements (specific to affiliated technology platforms and product candidates), product development and commercialization agreements, clinical trial agreements) that have been adopted by stakeholders engaged in this domain, during the period 2016-2021.

Chapter 10 provides a detailed analysis of various investments, such as venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings that were undertaken by companies engaged in this domain, during the period 2016-2021.

Chapter 11 features an elaborate discussion on the various commercialization strategies that can be adopted by drug developers engaged in this domain across different stages of therapy development, including prior to drug launch, at / during drug launch and post-marketing stage.

Chapter 12 presents an insightful market forecast analysis, highlighting the future potential of RAS targeting therapies, till 2030. We have segmented the market on the basis of [A] target indication (acute myeloid leukemia, colorectal cancer, head and neck cancer, lung cancer, ovarian cancer, pancreatic cancer, Phelan-Mcdermid syndrome and skin cancer), [B] type of molecule (biologic and small molecule), [C] type of therapy (monotherapy and combination therapy), [D] route of administration (intravenous, intramuscular, intradermal, intraocular, intraperitoneal, oral, and subcutaneous), and [E] key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World).

Chapter 13 is an appendix, which contains the list of companies and organizations mentioned in the report.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Global TROP2 Antibody Market & Clinical Trials Insight 2026

  • $ 2400
  • November 2021
  • 90 pages

Global TROP2 Antibody Market & Clinical Trials Insight 2026 Report Analysis and Data Highlights: • Research Methodology • Global & Regional Market Analysis • Global TROP2 Antibody Market Opportunity ...

  • World
  • Pharmaceutical
  • Lung Cancer
  • Industry analysis
  • Drug Approval

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on